{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:38Z","timestamp":1790916818098,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":167,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101292","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:48:42Z","timestamp":1783673322000},"page":"101292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort study"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-4320","authenticated-orcid":false,"given":"Cornelia A.M.","family":"Almekinders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess I.M.","family":"Snellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"van Ommen-Nijhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa G.","family":"Steenbruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.","family":"Klompenhouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels F.M.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert F.D.","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique E.M.M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry G.","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent O.","family":"Dezentj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2026.101292_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002204","article-title":"The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program \u201cCASCADE\u201d","volume":"13","author":"Savas","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctarc.2026.101292_bib0002","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-021-22605-2","article-title":"Genomic profile of advanced breast cancer in circulating tumour DNA","volume":"12","author":"Kingston","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctarc.2026.101292_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"Curtit","year":"2013","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101292_bib0004","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1056\/NEJMx120044","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"367","author":"Gerlinger","year":"2012","journal-title":"New England J Med."},{"key":"10.1016\/j.ctarc.2026.101292_bib0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101292_bib0006","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol."},{"key":"10.1016\/j.ctarc.2026.101292_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1367159","article-title":"Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy","volume":"2017","author":"Kelly","year":"2017","journal-title":"Int J Breast Cancer."},{"key":"10.1016\/j.ctarc.2026.101292_bib0008","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.21778","article-title":"Metastatic patterns in adenocarcinoma","volume":"106","author":"Hess","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101292_bib0009","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.21037\/jtd-22-536","article-title":"Oligoprogression in non-small cell lung cancer: a narrative review","volume":"14","author":"Nguyen","year":"2022","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.ctarc.2026.101292_bib0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol."},{"key":"10.1016\/j.ctarc.2026.101292_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115164","article-title":"Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer","volume":"215","author":"Milano","year":"2025","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctarc.2026.101292_bib0012","article-title":"Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor\u2013Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial","volume":"2","author":"David","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101292_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2024.09.002","article-title":"The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial","volume":"121","author":"Glicksman","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.ctarc.2026.101292_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2025.12.011","article-title":"Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer","author":"Colciago","year":"2026","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctarc.2026.101292_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.breast.2022.12.007","article-title":"Survival and prognostic factors in oligometastatic breast cancer","volume":"67","author":"Van Ommen-Nijhof","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101292_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-024-07542-0","article-title":"Treatment sequences and survival outcomes in advanced HR\u2009+\u2009HER2- breast cancer patients: a real-world cohort","volume":"210","author":"Almekinders","year":"2025","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101292_bib0017","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","article-title":"NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018","volume":"16","author":"Kalemkerian","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101292_bib0018","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctarc.2026.101292_bib0019","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"issue":"10422","key":"10.1016\/j.ctarc.2026.101292_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.ctarc.2026.101292_bib0021","author":"Tsai","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101292_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113422","article-title":"First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort","volume":"196","author":"Galvin","year":"2024","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctarc.2026.101292_bib0023","series-title":"Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10","article-title":"COntinue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study [abstract]","volume":"83","author":"Almekinders","year":"2023"},{"key":"10.1016\/j.ctarc.2026.101292_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023894","article-title":"Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis","volume":"12","author":"Kuo","year":"2022","journal-title":"Front Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:44Z","timestamp":1790913644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"alternative-id":["S2468294226002030"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101292","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101292"}}